Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Sigma-Aldrich Stories

2013-09-27 16:21:50

ST. LOUIS, Sept. 27, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and High Technology company (the "Company" or "Sigma-Aldrich"), announces a quarterly cash dividend of $0.215 per common share. The dividend was approved by the Company's Board of Directors on September 15, 2013 and is payable on December 13, 2013 to shareholders of record at the close of business on November 29, 2013. The Company also announces the election of Michael...

2013-09-25 08:22:28

Only St. Louis-Based Company to Make the List Earns Recognition for Increased Emphasis on Environmental Responsibility ST. LOUIS, Sept. 25, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and High Technology Company, was recently named to the Dow Jones Sustainability Indices (DJSI), a list of corporate sustainability leaders from around the globe. Companies listed in the DJSI have demonstrated best-in-class performance against numerous...

2013-09-19 23:04:35

MarketPublishers.com announces that a new research report on the 1,2-diaminopropane (CAS 78-90-0) market elaborated by BAC Reports is now available in its catalogue. London, UK (PRWEB) September 19, 2013 MarketPublishers.com announces that a new research report on the 1,2-diaminopropane (CAS 78-90-0) market elaborated by BAC Reports is now available in its catalogue. The newly published report “1,2-Diaminopropane (CAS 78-90-0) Market Research Report 2013” provides access to profound...

2013-09-19 08:27:59

ST. LOUIS, Sept. 19, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that SAFC(®) Commercial (www.sigma-aldrich.com/safc), its custom manufacturing services business unit, has engineered additional traits into its CHOZN(® )Platform cell line,( )increasing the utility of the CHOZN(®) portfolio of products and services. Two novel host cell lines have been added to the CHOZN(®) portfolio, yielded through SAFC's continuous research and development. The...

2013-09-18 08:30:57

RICHMOND, Calif., Sept. 18, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the sale of 6,100,000 shares of its common stock in an underwritten public offering at a price to the public of $10.58 per share, the closing price of the stock on the previous day. The gross proceeds to Sangamo from the public offering are expected to be approximately $65 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In...

2013-09-18 08:28:30

Sigma-Aldrich Corporation, in Collaboration with The American Association for the Advancement of Science (AAAS), Produces First-Ever "State of Translational Research Survey Report" ST. LOUIS, Sept. 18, 2013 /PRNewswire/ -- Sigma-Aldrich( )Corporation (NASDAQ: SIAL) today released a report on the state of academic translational research, a rapidly expanding field in which academic scientists aim to "translate" their laboratory discoveries to patient benefit. The first-of-its-kind...

2013-09-17 16:23:47

RICHMOND, Calif., Sept. 17, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Sangamo also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the...

2013-09-04 08:23:13

ST. LOUIS, Sept. 4, 2013 /PRNewswire/ -- Sigma-Aldrich(®) Corporation's (NASDAQ: SIAL) BioReliance(®) (www.bioreliance.com), the biologics and early-development services business under SAFC (www.sigmaaldrich.com/safc), has opened a new Clearance Services facility in Rockville, MD. This world-class facility, commissioned on August 1, 2013, allows BioReliance to offer increased capacity and flexible scheduling while maintaining its core focus on providing industry-leading quality,...

2013-09-03 08:27:16

Horizon to utilize both nuclease and rAAV gene editing platforms in custom cell-line generation services and creation of genetically-defined cell line products ST. LOUIS, Sept. 3, 2013 /PRNewswire/ -- Sigma-Aldrich(®) Corporation (Nasdaq: SIAL) today announced that Sigma(®) Life Science, its innovative biological products and services business, has entered a non-exclusive license agreement with Horizon Discovery for use of Sigma's CompoZr(®) Zinc Finger Nuclease (ZFN) technology....

2013-09-01 23:02:08

Proteomics Market research report categorizes the global proteomics market into instrumentation technology, reagents, and services. http://www.marketsandmarkets.com/Market-Reports/proteomics-market-731.html (PRWEB) September 01, 2013 The “Proteomics Market (Protein Microarray, Mass Spectrometry, NMR Spectroscopy, Chromatography, Electrophoresis, Surface Plasmon Resonance, Protein Fractionation, X-ray Crystallography, Immunoassay) - Instruments, Reagents and Services - Trends and Global...